Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?

Sreenivasa Chandana; Daruka Mahadevan

doi:10.1017/S1462399409001240

Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?

Published online by Cambridge University Press: 17 November 2009

Sreenivasa Chandana and

Daruka Mahadevan

Show author details

Sreenivasa Chandana: Affiliation:
Michigan State University, Department of Medicine, East Lansing, MI, USA.
Daruka Mahadevan*: Affiliation:
Arizona Cancer Center, Section of Hematology/Oncology, Tucson, AZ, USA.
*: *Corresponding author: Daruka Mahadevan, 1515 N. Campbell Avenue, Tucson, AZ 85724, USA. Tel: +1 520 626 4331; Fax: +1 520 626 2225; E-mail: [email protected]

Article contents

Abstract
References

Get access

Rights & Permissions

Abstract

Biological complexity, inaccessible anatomical location, nonspecific symptoms, lack of a screening biomarker, advanced disease at presentation and drug resistance epitomise pancreatic ductal adenocarcinoma (PDA) as a poor-prognosis, lethal disease. Twenty-five years of research (basic, translational and clinical) have barely made strides to improve survival, mainly because of a fundamental lack of knowledge of the biological processes initiating and propagating PDA. However, isolation of pancreas cancer stem cells or progenitors, whole-genome sequencing for driver mutations, advances in functional imaging, mechanistic dissection of the desmoplastic reaction and novel targeted therapies are likely to shed light on how best to treat PDA. Here we summarise current knowledge and areas where the field is advancing, and give our opinion on the research direction the field should be focusing on to better deliver promising therapies for our patients.

Type: Review Article
Information: Expert Reviews in Molecular Medicine , Volume 11 , July 2009 , e34

DOI: https://doi.org/10.1017/S1462399409001240 [Opens in a new window]
Copyright: Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Jemal, A. et al. (2007) Cancer Statistics. CA Cancer Journal of the Clinic 57, 43-66CrossRef Google Scholar PubMed

2Klein, A.P. et al. (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Research 64, 2634-2639CrossRef Google Scholar PubMed

3Lowenfels, A.B. et al. (2001) Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. Journal of the American Medical Association 286, 169-170CrossRef Google Scholar PubMed

4Lowenfels, A.B. et al. (1993) Pancreatitis and the risk of pancreas cancer. International Pancreatitis Study Group. New England Journal of Medicine 328, 1433-1437CrossRef Google Scholar PubMed

5Gullo, L., Pezzilli, R. and Morselli-Labate, A.M. (1994) Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group. New England Journal of Medicine 331, 81-84CrossRef Google Scholar

6Everhart, J. and Wright, D. (1995) Diabetes mellitus as a risk factor for pancreatic cancer. A meta analysis. Journal of the American Medical Association 273, 1605-1609CrossRef Google Scholar PubMed

7Permert, J. et al. (1993) Improved glucose metabolism after subtotal pancreatectomy for pancreas cancer. British Journal of Surgery 80, 1047-1050CrossRef Google Scholar

8Canto, M.I. (2007) Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Seminars in Oncology 34, 295-302CrossRef Google Scholar PubMed

9Neoptolemos, J.P. et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreas cancer. New England Journal of Medicine 350, 1200-1210CrossRef Google Scholar

10Alexakis, N. et al. (2004) Current standards of surgery for pancreatic cancer. British Journal of Surgery 91, 1410-1427CrossRef Google Scholar PubMed

11Kim, H.J. et al. (2002) Does neoadjuvant chemoradiation downstage locally advanced pancreas cancer? Journal of Gastrointestinal Surgery 6, 763-769CrossRef Google Scholar

12Oettle, H. and Neuhaus, P. (2007) Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs 67, 2293-2310CrossRef Google Scholar PubMed

13Burris, H.A. et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. Journal of Clinical Oncology 15, 2403-2413CrossRef Google Scholar PubMed

14Cartwright, T., Richards, D.A. and Boehm, K.A. (2008) Cancer of the pancreas: are we making progress? a review of studies in the US Oncology Research Network. Cancer Control 15, 308-313CrossRef Google Scholar PubMed

15Von Hoff, D.D. (2006) What's new in pancreatic cancer treatment pipeline? Best Practice & Research: Clinical Gastroenterology 20, 315-26CrossRef Google Scholar PubMed

16Rubio-Viqueira, B. et al. (2006) An in vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Research 12, 4652-4661CrossRef Google Scholar

17Olive, K.P. and Tuveson, D.A. (2006) The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clinical Cancer Research 12, 5277-5287CrossRef Google Scholar PubMed

18Jones, S., Zhang, X. and Parsons, D.W. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806CrossRef Google Scholar PubMed

19Han, H. et al. (2002) Identification of differentially expressed genes in pancreatic cancer cells using cdna microarray. Cancer Research 62, 2890-2896Google Scholar PubMed

20Crnogorac-Jurcevic, T. et al. (2002) Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21, 4587-4594CrossRef Google Scholar PubMed

21Iacobuzio-Donahue, C.A. et al. (2003) Exploration of global gene expression patterns in pancreatic adenocarcinoma using cdna microarrays. American Journal of Pathology 162, 1151-1162CrossRef Google Scholar PubMed

22Iacobuzio-Donahue, C.A. et al. (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Research 63, 8614-8622Google Scholar PubMed

23Campagna, D. et al. (2008) Gene expression profiles associated with advanced pancreatic cancer. International Journal of Clinical Experimental Pathology 1, 32-43Google Scholar PubMed

24Mahadevan, D. and Von Hoff, D.D. (2007) Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Molecular Cancer Therapeutics 6, 1186-1197CrossRef Google Scholar PubMed

25Apte, M.V. et al. (2004) Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29, 179-187CrossRef Google Scholar PubMed

26Menke, A. and Adler, G. (2002) TGFbeta-induced fibrogenesis of the pancreas. International Journal of Gastrointestinal Cancer 31, 41-46CrossRef Google Scholar PubMed

27Infante, J.R., Matsubayashi, H. and Sato, N. (2007) Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. Journal of Clinical Oncology 25, 319-25CrossRef Google Scholar PubMed

28Hruban, R.H. et al. (2000) Progression model for pancreatic cancer. Clinical Cancer Research 6, 2969-2972Google Scholar PubMed

29Maitra, A. et al. (2005) Precursors to invasive pancreatic cancer. Advances in Anatomic Pathology 12, 81-91CrossRef Google Scholar PubMed

30Ishikawa, O. et al. (1999) Minute carcinoma of the pancreas measuring 1 cm or less in diameter – Collective review of Japanese case reports. Hepatogatroenterology 46, 8-15Google Scholar PubMed

31Gangi, S. et al. (2004) Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer. Retrospective review of CT scans obtained before diagnosis. American Journal of Roentgenology 182, 897-903CrossRef Google Scholar

32Benson, A.B. et al. (2003) Pancreatic, neuroendocrine GI and adrenal cancers. In Cancer Management: A Multidisciplinary Approach (7th edn) (Pazdur, R. et al. , eds), pp. 273-302, CMP MedicaGoogle Scholar

33Bissell, M.J. and Radisky, D. (2001) Putting tumors in context. Nature Reviews Cancer 1, 46-54CrossRef Google Scholar PubMed

34Chifenti, B. et al. (2008) Establishment and characterization of 4 new human pancreatic cancer cell lines. Evidences of different tumor phenotypes. Pancreas 38, 184-196Google Scholar

35Bruns, C.J. et al. (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clinical Cancer Research 6, 1936-1948Google Scholar PubMed

36Riley, C.J. et al. (2009) Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Research 69, 1933-1940CrossRef Google Scholar PubMed

37Hingorani, S.R. et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450CrossRef Google Scholar PubMed

38Aguirre, A.J. et al. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Development 17, 3112-3126CrossRef Google Scholar PubMed

39Hingorani, S.R. et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483CrossRef Google Scholar PubMed

40Izeradjene, K. et al. (2007) KrasG12D and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11, 299-243/endpage>CrossRef Google Scholar PubMed

41Takaku, K. et al. (1998) Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92, 645-656CrossRef Google Scholar PubMed

42Velculescu, V.E. et al. (1995) Serial analysis of gene expression. Science 270, 484-487CrossRef Google Scholar PubMed

43Kim, H.N. et al. (2007) Gene expression profiling in lymph node-positive and lymph-node negative pancreatic cancer. Pancreas 34, 325-334CrossRef Google Scholar PubMed

44Collisson, E.A. et al. (2008) Use of whole genome expression analysis of pancreatic adenocarcinoma to predict prognosis after surgery. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4503CrossRef Google Scholar

45Mori, R. et al. (2008) Different pancreatic cancer genomic risk prediction models derived from microdissected and non-microdissected paraffin-embedded tissue. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4622CrossRef Google Scholar

46Bonnet, D. and Dick, J.E. (1997) Human acute myeloid leukemia is organized as a hierachy that originates from a primitive hematopoietic cell. Nature Medicine 3, 730-737CrossRef Google Scholar

47Al-Hajj, M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 100, 3983-3988CrossRef Google Scholar PubMed

48Simeone, D.M. (2008) Pancreatic cancer stem cells: implications for the treatment of pancreas cancer. Clinical Cancer Research 14, 5646-5648CrossRef Google Scholar

49Li, C. et al. (2007) Identification of pancreatic cancer stem cells. Cancer Research 67, 1030-1037CrossRef Google Scholar PubMed

50Hermann, P.C. et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreas cancer. Cell Stem Cell 1, 313-323CrossRef Google Scholar

51American Joint Committee on Cancer. (2002) Exocrine pancreas. In American Joint Committee on Cancer: AJCC Cancer Staging Manual (6th edn), pp. 157-164, Springer, New York, USAGoogle Scholar

52Katz, M.H. et al. (2008) Tumor-node-metastasis staging of pancreatic adenocarcinoma. Cancer Journal of the Clinic 58, 111-125CrossRef Google Scholar PubMed

53Katz, M.H. et al. (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. Journal of the American College of Surgery 206, 833-846CrossRef Google Scholar PubMed

54Glanemann, M. et al. (2008) Surgical strategies for treatment of malignant pancreas tumors: extended, standard or local surgery? World Journal of Surgical Oncology 6, 1-10CrossRef Google Scholar PubMed

55Ujiki, M.B. and Talamonti, M.S. (2007) Guidelines for the surgical management of pancreatic adenocarcinoma. Seminars in Oncology 34, 311-320CrossRef Google Scholar PubMed

56Tanaka, M. (2004) Intraductal papillary mucinous neoplasm of the pancreas. Pancreas 28, 282-288CrossRef Google Scholar PubMed

57Levy, M.J. et al. (2005) Endoscopic ultrasound-guided trucut biopsy of the cyst wall for diagnosing cystic pancreatic tumors. Clinical Gastroenterology and Hepatology 3, 974-979CrossRef Google Scholar PubMed

58Moore, M.J. et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 25, 1960-1966CrossRef Google Scholar PubMed

59O'Reilly, E.M. and Abou-Alfa, G.K. (2007) Cytotoxic therapy for advanced pancreatic adenocarcinoma. Seminars in Oncology 34, 347-353CrossRef Google Scholar PubMed

60Pelzer, U. et al. (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4508CrossRef Google Scholar

61Poplin, E. et al. (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 27, 3778-3785CrossRef Google Scholar PubMed

62Vervenne, W. et al. (2008) A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4507CrossRef Google Scholar

63Von Hoff, D.D., Mahadevan, D. and Bearss, D.J. (2001) New developments in the treatment of patients with pancreatic cancer. Clinical Oncology Updates 4, 1-15Google Scholar

64Burtness, B.A. et al. (2007) Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor (EGF-r): Eastern Cooperative Oncology. Journal of Clinical Oncology 25 (June 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4519CrossRef Google Scholar

65Drengler, R.L. et al. (2008) Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 15523CrossRef Google Scholar

66Smith, L.S. et al. (2008) SPARC and CA19-9 as biomarkers in patients with advanced pancreatic cancer treated with nab paclitaxel plus gemcitabine. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 15592CrossRef Google Scholar

67Löhr, M. et al. (2009) A phase II trial of cationic liposomal paclitaxel in combination with gemcitabine in patients with unresectable pancreatic cancer. 2009 ASCO Gastrointestinal Cancers Symposium, Abstract LBA120, http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10270 Google Scholar

68Berman, D.M. et al. (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846-851CrossRef Google Scholar PubMed

69Taipale, J. and Beachy, P.A. (2001) The Hedgehog and Wnt signaling pathways in cancer. Nature 411, 349-354CrossRef Google Scholar

70Thayer, S.P. et al. (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425, 851-856CrossRef Google Scholar PubMed

71Morton, J.P. et al. (2007) Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 104, 5103-5108CrossRef Google Scholar PubMed

72Prasad, N.B. et al. (2005) Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Research 65, 1619-1626CrossRef Google Scholar PubMed

73Pasca di Magliano, M. and Hebrok, M. (2003) Hedgehog signaling in cancer formation and maintenance. Nature Review Cancer 3, 903-911CrossRef Google Scholar PubMed

74Ji, Z. et al. (2007) Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. Journal of Biological Chemistry 282, 14048-14055CrossRef Google Scholar PubMed

75Nolan-Stevaux, O. et al. (2008) GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes and Development 23, 24-36CrossRef Google Scholar

76Yauch, R.L. et al. (2008) A paracrine requirement for hedgehog signaling in cancer. Nature 455, 406-410CrossRef Google Scholar

77Feldmann, G. et al. (2007) Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Research 67, 2187-2196CrossRef Google Scholar PubMed

78Jimeno, A. et al. (2009) A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Molecular Cancer Therapeutics 8, 310-314CrossRef Google Scholar PubMed

79LoRusso, P.M. et al. (2008) A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 3516CrossRef Google Scholar

80Travaglione, V. et al. (2008) Activity of IPI-926, a novel inhibitor of the Hh pathway, in subcutaneous and orthotopically implanted xenograft tumors that express SHh ligand. Presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (21–24 October 2008; Geneva, Switzerland), poster 570, http://www.infi.com/pipeline-archives/INFI%20IPI-926%20tumor%20stroma%20-%20EORTC%202008.pdf Google Scholar

81Iacobuzio-Donahue, C.A. et al. (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. Journal of Clinical Oncology 27, 1806-1813CrossRef Google Scholar PubMed

82Singh, J. et.al. (2003) Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorganismal Medicine Chemistry Letters 13, 4355-4359CrossRef Google Scholar PubMed

83Melisi, D. et al. (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Molecular Cancer Therapeutics 7, 829-840CrossRef Google Scholar PubMed

84Gaspar, N.J. et al. (2007) Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Molecular Pharmacology 72, 152-161CrossRef Google Scholar PubMed

85Ottaviano, A.J. et al. (2006) Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Research 66, 7032-7040CrossRef Google Scholar PubMed

86Ohuchida, K. et al. (2004) Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Research 64, 3215-3222CrossRef Google Scholar PubMed

87Michieli, P. et al. (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73CrossRef Google Scholar PubMed

88Garber, K. (2007) Notch emerges as new cancer drug target. Journal of the National Cancer Institute 99, 1284-1285CrossRef Google Scholar PubMed

89Wang, Z. et al. (2006) Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Molecular Cancer Therapeutics 5, 483-493CrossRef Google Scholar PubMed

90Iseki, H. et al. (1998) A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. Journal of Gastrointestinal Surgery 2, 36-43CrossRef Google Scholar PubMed

91Howard, S. et al. (2009) Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. Journal of Medicinal Chemistry 52, 379-88CrossRef Google Scholar PubMed

92Ashwell, S., Janetka, J.W. and Zabludoff, S. (2008) Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opinion on Investigational Drugs 17, 1331-1340CrossRef Google Scholar PubMed

93Ito, D. et al. (2006) In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. International Journal of Cancer 118, 2337-2343CrossRef Google Scholar PubMed

94Wolpin, B.M. et al. (2009) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. Journal of Clinical Oncology 27, 193-198CrossRef Google Scholar PubMed

95Engelhardt, K. et al. (2006) Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma. Current Drug Discovery Technology 3, 231-243CrossRef Google Scholar PubMed

96Wenger, C. et al. (1999) Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 18, 1073-1080CrossRef Google Scholar PubMed

97Ryu, B. et al. (2001) Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Research 61, 1833-1838Google Scholar PubMed

98Dornhöfer, N. et al. (2006) Connective tissue growth factor specific mAb therapy inhibits pancreatic tumor growth and metastasis. Cancer Research 66, 5817-5827CrossRef Google Scholar

99Burns, W.C. et al. (2006) Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. Journal of the American Society of Nephrology 17, 2484-2494CrossRef Google Scholar PubMed

100Thomas, R.M. et al. (2007) The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreas cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Research 67, 6075-6082CrossRef Google Scholar PubMed

101O'Toole, J.M. et al. (2006) Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-Met family member. Cancer Research 66, 9162-9170CrossRef Google Scholar

102Bauer, T.W. et al. (2005) Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met and insulin-like growth factor-1 receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Research 65, 7775-7781CrossRef Google Scholar PubMed

103Stahel, R.A. and Zangemeister-Wittke, U. (2003) Antisense oligonucleotides for cancer therapy-an overview. Lung Cancer 41 (Suppl 1), S81-8CrossRef Google Scholar PubMed

104Jolivet, J. et al. (2008) A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 3541CrossRef Google Scholar

105Seymour, A.B. et al. (1994) Allelotype of pancreatic adenocarcinoma. Cancer Research 54, 2761-2764Google Scholar PubMed

106Clark, C.E. et al. (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Research 67, 9518-9527CrossRef Google Scholar

107Clark, C.E., Beatty, G.L. and Vonderheide, R.H. (2009) Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Letters 279, 1-7CrossRef Google Scholar PubMed

108Masamune, A. et al. (2009) Fibronogen induces cytokine and collagen production in pancreatic stellate cells. Gut 58, 550-559CrossRef Google Scholar

109Hwang, R.F. et al. (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Research 68, 918-926CrossRef Google Scholar PubMed

110Bailey, J.M. et al. (2008) Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clinical Cancer Research 14, 5995-6004CrossRef Google Scholar PubMed

111Bipat, S. et al. (2005) Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. Journal of Computer Assisted Tomography 29, 438-445CrossRef Google Scholar PubMed

112Dewitt, J. et al. (2006) Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clinical Gastroenterology and Hepatology 4, 717-725CrossRef Google Scholar PubMed

113Farma, J.M. et al. (2007) PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Annals of Surgical Oncology 15, 2465-2471CrossRef Google Scholar

114Levy, M.J. (2007) Endoscopic ultrasound-guided Trucut biopsy of the pancreas: prospects and problems. Pancreatology 7, 163-166CrossRef Google Scholar PubMed

115Mertz, H.R. et al. (2000) EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointestinal Endoscopy 52, 367-371CrossRef Google Scholar PubMed

116Chari, S.T. et al. (2007) Detecting early pancreatic cancer: problems and prospects. Seminars in Oncology 34, 284-294CrossRef Google Scholar

117Canto, M.I. et al. (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clinical Gastroenterology and Hepatology 4, 766-781CrossRef Google Scholar PubMed

118Fukushima, H. et al. (2006) Diagnostic value of curved multiplanar reformatted images in multislice CT for the detection of resectable pancreatic ductal adenocarcinoma. European Radiology 16, 1709-1718CrossRef Google Scholar PubMed

119Chang, K.J. (2006) State of the art lecture: endoscopic ultrasound (EUS) and FNA in pancreatico-biliary tumors. Endoscopy 38 (Suppl 1), S56-S60CrossRef Google Scholar PubMed

120Brand, R.E. et al. (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56, 1460-1469CrossRef Google Scholar PubMed

121Rosch, T. et al. (2000) Endoscopic ultrasound criteria for vascular invasion in the staging of cancer of the head of the pancreas: a blind reevaluation of videotapes. Gastrointestinal Endoscopy 52, 469-477CrossRef Google Scholar PubMed

122Meining, A. et al. (2002) You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging. Gut 50, 599-603CrossRef Google Scholar PubMed

123Meining, A. et al. (2003) High interobserver variability in endosonographic staging of upper gastrointestinal cancers. Gastroenterology 41, 391-394Google Scholar PubMed

124Beyer, T., Townsend, D.W. and Blodgett, T.M. (2002) Dual-modality PET/CT tomography for clinical oncology. Quarterly Journal of Nuclear Medicine 46, 24-34Google Scholar PubMed

125Heinrich, S. et al. (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Annals of Surgery 242, 235-243CrossRef Google Scholar PubMed

126Kashiwagi, H. et al. (2007) Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Molecular Cancer 15, 6-48Google Scholar

127Shields, A.F. et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Medicine 4, 1334-1336CrossRef Google Scholar PubMed

128Herrmann, K. et al. (2008) In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. Journal of Nuclear Medicine 49, 1437-1444CrossRef Google Scholar PubMed

129Mitsuoka, K. et al. (2008) Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H + /peptide transporter. Journal of Nuclear Medicine 49, 615-622CrossRef Google Scholar PubMed

130Weissleder, R. and Pittet, M.J. (2008) Imaging in the era of molecular oncology. Nature 452, 580-589CrossRef Google Scholar PubMed

131Min, J.J. and Gambhir, S.S. (2008) Molecular imaging of PET reporter gene expression. Handbook of Experimental Pharmacology 185, 277-303CrossRef Google Scholar

132Kelly, K.A. et al. (2008) Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Medicine 5, e85CrossRef Google Scholar PubMed

133Hamanaka, Y. et al. (2003) Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. International Journal of Cancer 103, 97-100CrossRef Google Scholar PubMed

134Raedle, J. et al. (1996) p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 13, 241-246CrossRef Google Scholar PubMed

135Maacke, H. et al. (2002) Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. Journal of Cancer Research in Clinical Oncology 128, 219-222CrossRef Google Scholar PubMed

136Xia, Q. et al. (2005) Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochemistry and Biophysics Research Community 330, 526-532CrossRef Google Scholar PubMed

137Koopmann, J. et al. (2004) Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention 13, 487-491CrossRef Google Scholar PubMed

138Koopmann, J. et al. (2004) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clinical Cancer Research 10, 2386-2392CrossRef Google Scholar PubMed

139Koopmann, J. et al. (2006) Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clinical Cancer Research 12, 442-446CrossRef Google Scholar PubMed

140Simeone, D.M. et al. (2007) CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34, 436-443CrossRef Google Scholar PubMed

141Koopmann, J. et al. (2004) Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clinical Cancer Research 10, 860-868CrossRef Google Scholar PubMed

142Argani, P. et al. (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clinical Cancer Research 7, 3862-3868Google Scholar PubMed

143Faca, V.M. et al. (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Medicine 5, e123CrossRef Google Scholar PubMed

144Goggins, M. (2007) Identifying molecular markers for the early detection of pancreatic neoplasia. Seminars in Oncology 34, 303-310CrossRef Google Scholar PubMed

145Gronborg, M. et al. (2004) Comprehensive proteomic analysis of human pancreatic juice. Journal of Protein Research 3, 1042-1055CrossRef Google Scholar PubMed

146Chen, R. et al. (2006) Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 6, 3871-3879CrossRef Google Scholar PubMed

147Chen, R. et al. (2007) Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 34, 70-79CrossRef Google Scholar PubMed

148Zhou, L. et al. (2007) Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics 7, 1345-1355CrossRef Google Scholar PubMed

149Zhao, J. et al. (2007) Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. Journal of Proteome Research 6, 1864-1874CrossRef Google Scholar PubMed

150Lu, J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435, 834-838CrossRef Google Scholar PubMed

151Bittner, M. et al. (2006) Frequency of potential therapeutic targets identified by immnuohistochemistry and DNA microarray in tumors from patients who have progressed on multiple therapeutic agents. Journal of Clinical Oncology 24, 18s-138sGoogle Scholar

152Olive, K.P. et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461CrossRef Google Scholar

153Elroy, M. et al. (2008) Color-coded imaging of splenocyte-pancreatic cancer cell interactions in the tumor microenvironment. Cell Cycle 7, 2916-2921Google Scholar

154Mueller, M-T. et al. (2009) Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137, 1102-1113CrossRef Google Scholar PubMed

155Deramaudt, T.B. et al. (2006) N-Cadherin and keratinocyte growth factor receptor mediate the functional interplay between Ki-Ras G12V and p53 V143A in promoting pancreatic cell migration, invasion and tissue architecture disruption. Molecular and Cellular Biology 26, 4185-4200CrossRef Google Scholar

156Kuang, C. et al. (2006) In vivo disruption of TGF-β signaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proceedings of the National Academy of Sciences of the United States of America 103, 1858-1863CrossRef Google Scholar PubMed

157Cindy, Y.F. et al. (2005) Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Research 65, 1497-1504Google Scholar

158Fuhrman, G. et al. (1994) Thin section contrast enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. American Journal of Surgery 167, 104-113CrossRef Google Scholar PubMed

159Moertel, C.G. et al. (1981) Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48, 1705-17103.0.CO;2-4>CrossRef Google Scholar PubMed

160Chauffert, B. et al. (2008) Phase III trial comparing intensive induction chemotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Annals of Oncology 19, 1592-1599CrossRef Google Scholar PubMed

161Kalser, M.H. and Ellenberg, S.S. (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Archives of Surgery 120, 899-903Google Scholar PubMed

162Regine, W.F. et al. (2006) RTOG 9704 a Phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine for resected pancreatic adenocarcinoma. Journal of Clinical Oncology 24 (June 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4007CrossRef Google Scholar

163Oettle, H. et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized control trial. Journal of the American Medical Association 297, 267-277CrossRef Google Scholar

164Neuhaus, P. et al. (2008) CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings) Abstract LBA4504CrossRef Google Scholar

165Loehrer, P.J. et al. (2008) A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. Journal of Clinical Oncology 26 (May 20 Suppl: ASCO Annual Meetings Proceedings), Abstract 4506CrossRef Google Scholar

Article contents

Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?

Abstract

Access options

References

References

Further reading, resources and contacts

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?

Abstract

Access options

References

References

Further reading, resources and contacts

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests